What’s Driving Immuron’s (ASX:IMC; NASDAQ:IMRN) Pipeline Progress and FY26 Outlook?

Highlights

• Immuron has reported HY26 sales of A$4.2 million, reflecting a 5% increase on HY25.
• Travelan® helps prevent travellers’ diarrhea by targeting harmful gut bacteria.
• The company received FDA approval for IMM-529 Investigational New Drug application for Phase 2 trial.
• Immuron secured a new US Department of Defense award targeting Campylobacter and Shigella.
• The company expanded its product offering with the launch of ProIBS® in Australia.
• Net assets increased to A$13.07 million, supported by cash reserves of A$10.00 million at 31 December, 2025.

Australian biotechnology player Immuron Limited (ASX: IMC; NASDAQ: IMRN) is positioning its oral antibody platform at the intersection of infectious disease prevention and gastrointestinal health, as recent updates highlight progress across commercial products, clinical development, and financial metrics.

From expanding the reach of its flagship product Travelan® to advancing clinical-stage candidate IMM-529 into Phase 2 readiness, the company’s activities reflect a pipeline spanning both near-term revenue generation and ongoing research initiatives.

Alongside this, new funding support, product launches, and improved balance sheet metrics provide additional context to its FY26 trajectory, with management outlining expectations for growth across key financial indicators in the second half of the year.

Platform-Based Approach

Immuron’s technology platform is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. This approach enables the development of orally administered therapies designed to target pathogens within the gastrointestinal tract —an area often underserved by traditional treatments.

The platform underpins multiple product candidates and supports ongoing collaborations, including vaccine development efforts with Monash University, highlighting its broader scientific relevance.

Travelan® : Commercial Traction in Motion

Immuron’s lead product, Travelan® is an orally administered passive immunotherapy designed to reduce the likelihood of contracting travelers’ diarrhea. The product has a tabletized preparation of hyper-immune bovine antibodies that bind to diarrhea-causing bacteria and help prevent colonisation.

It is listed on the Australian Register for Therapeutic Goods and licensed in Canada as a natural health product, while in the United States, it is marketed as a dietary supplement for digestive tract protection. Travelan® is based on the IMM-124E formulation developed using Immuron’s platform.

Pipeline Progress

Immuron continues to advance its clinical pipeline with IMM-529, which is being developed as an adjunctive therapy alongside standard antibiotics for recurrent Clostridioides difficile infection. The company received FDA approval for its Investigational New Drug application, paving the way for Phase 2 clinical trials.

Further strengthening its R&D credentials, the company has secured funding from the US Department of Defense to develop oral therapeutics targeting Campylobacter and Shigella.

Expanded Product Portfolio

Beyond infectious diseases, Immuron has entered the gastrointestinal health segment through ProIBS®. The company holds exclusive distribution rights in Australia and New Zealand under an agreement with Calmino Group AB. ProIBS® is a certified medical device indicated for managing symptoms of irritable bowel syndrome, including abdominal pain, bloating, and irregular bowel movements.

Strengthening Financial Foundations

For the half-year ended 31 December 2025, Immuron’s revenue from ordinary activities reached A$4.18 million, compared with A$3.99 million in the prior corresponding period. Gross profit was reported at A$2.65 million, while operating profit from hyperimmune products stood at A$0.98 million. Net assets increased to A$13.07 million from A$8.07 million as at 30 June 2025, supported by cash reserves of A$10.00 million, up from A$2.83 million.

As the company progresses through FY26, it reported HY26 performance alongside an outlook indicating continued momentum into the second half. Net sales for both 2H FY26 and the full year are projected to exceed the prior corresponding period, supported by ongoing business activities. In addition, net sales, net profit, and EBITDX (excluding R&D) are all expected to surpass pcp levels, reflecting anticipated improvement across key financial metrics.

IMC shares traded at AUD 0.028 on 30 March 2026.